With 2016’s wild-card Republican primary candidate becoming 2017’s POTUS, the list of outstanding questions confronting biotech this year is particularly long.

Biotech, like all other industries and the British public, is no closer to knowing what life will look like post-Brexit than it was on June 24.

At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017…

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…

The FDA has granted priority review status and a June 30 PDUFA date to Tesaro’s PARP inhibitor niraparib.

Clovis Oncology has won approval for rucaparib in a particular population of ovarian cancer patients.

Loxo Oncology reckons it could be just a year or so away from being able to file for approval of its lead drug, just months after reporting phase 1 data.

Purdue has signed a new deal with Japanese drugmaker Shionogi that will see the pair work together to sell in the U.S. the latter’s opioid-induced constipation…

Agios has called time on one of its drug candidates for rare inherited disease PK deficiency—but stressed that the lead drug in the program is still on track.